Event arc
This startup could transform drug discovery by applying advanced AI techniques.
AI BriefWire / Thread
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
OpenAI researcher Miles Wang is planning to launch an AI drug discovery startup valued at $2 billion. The startup aims to leverage AI to accelerate drug development processes. Lightspeed is reportedly in talks to lead the funding round.
TechCrunch AI
Signal trust
Single sourceEarly signal
Companies involved
OpenAI
Market lens
It may attract significant investment and drive innovation in pharmaceutical R&D.
Operator take
Companies should monitor AI advancements in drug discovery for potential collaboration or competition.
Source mix
Sources in this thread (1): TechCrunch AI
How the thread developed
Read the development of the event across sources, timestamps, and editorial cues.
Latest signal
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
OpenAI researcher Miles Wang is planning to launch an AI drug discovery startup valued at $2 billion. The startup aims to leverage AI to accelerate drug development processes. Lightspeed is reportedly in talks to lead the funding round.
Stories in this cluster
Open individual briefings or jump to the original reporting.
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
OpenAI researcher Miles Wang is planning to launch an AI drug discovery startup valued at $2 billion. The startup aims to leverage AI to accelerate drug development processes. Lightspeed is reportedly in talks to lead the funding round.